• Pathogenicity of Wild-Type vs E3-Deleted Canine Adenovirus 2

  2026-05-09

  This study identifies and characterizes a novel canine adenovirus type 2 (CAdV-2) strain with a 9-nucleotide E3 gene deletion, assessing its pathogenicity in dogs compared to wild-type strains. Findings reveal that the E3-deleted variant retains virulence, suggesting functional redundancy in this genomic region and informing future vaccine strategies.

• Perphenazine: Precision Dopamine D2 Antagonism & Host Immuni

  2026-05-09

  Explore Perphenazine as a dopamine D2 receptor antagonist with unique dual roles in neuropharmacology and host-directed immunity. This article offers an advanced, application-focused perspective, bridging in vitro assay design with the latest insights into phenothiazine-induced antibacterial mechanisms.

• Reliable PCR for Cell Assays: 2X Taq PCR Master Mix (with dy

  2026-05-08

  This article addresses real laboratory challenges in cell viability, proliferation, and cytotoxicity assays, demonstrating how the 2X Taq PCR Master Mix (with dye) (SKU K1034) ensures reproducibility and workflow efficiency. Scenario-driven Q&A blocks offer evidence-based solutions and practical guidance for biomedical researchers and technicians seeking dependable PCR amplification and TA cloning.

• IL-17A as a Prognostic Biomarker in GBS-Colonized Pregnancie

  2026-05-07

  This study identifies maternal IL-17A as a predictive biomarker for neonatal invasive disease in Group B Streptococcus (GBS)-colonized pregnancies. By profiling cytokine responses and leveraging TLR1/2 pathway activation ex vivo, the research enhances understanding of maternal-neonatal immune risk and informs future translational approaches.

• Synergistic CDK4/6 and BET Inhibition in Pancreatic Cancer v

  2026-05-07

  Gu et al. (2025) demonstrate that combining CDK4/6 and BET inhibitors synergistically suppresses pancreatic tumor growth and reverses EMT by modulating the GSK3β-mediated Wnt/β-catenin pathway. This mechanistic insight clarifies a previously unappreciated risk of CDK4/6 monotherapy and highlights the therapeutic potential of dual pathway targeting in pancreatic ductal adenocarcinoma.

• pH-Sensitive Nanoparticles Reverse Drug Resistance in BCSCs

  2026-05-06

  This study demonstrates a pH-responsive nanoparticle system co-delivering all-trans retinoic acid (ATRA) and schisandrin B (SchB) to overcome multidrug resistance in breast cancer stem cells (BCSCs). The innovation lies in targeted delivery and metabolic disruption, which substantially improves cytotoxic efficacy against resistant BCSCs and provides a new paradigm for addressing chemoresistance in breast cancer.

• Alfuzosin HCl: Applied Protocols in α1 Adrenoceptor Antagoni

  2026-05-06

  Alfuzosin HCl from APExBIO empowers researchers with high specificity and uroselectivity for in vitro and translational benign prostatic hyperplasia (BPH) research. This guide translates clinical and mechanistic insights into actionable workflows, including advanced assay design and troubleshooting strategies for α1-adrenergic receptor signaling studies.

• Protease Inhibitor Cocktail EDTA-Free: Safeguarding Plant Pr

  2026-05-05

  Unlock advanced strategies for plant cell protein stability using a Protease Inhibitor Cocktail in m6A and RNA modification-focused workflows. This article uniquely integrates protein degradation inhibition with insights from cutting-edge plant immunity research.

• Deferasirox Fe3+ Chelate: Precision Iron Chelation in Metabo

  2026-05-05

  Deferasirox Fe3+ chelate (Exjade) from APExBIO is redefining how iron overload and metabolic adaptation are modeled in the lab. This article delivers actionable protocols, mechanistic insight, and troubleshooting strategies for leveraging high-purity iron chelation in advanced cell stress and beta-thalassemia research.

• HBsAg Hijacks TBK1 to Suppress Interferon and Induce Autopha

  2026-05-04

  This study reveals that hepatitis B surface antigen (HBsAg) impairs innate immunity by hijacking TANK-binding kinase 1 (TBK1), suppressing type I interferon signaling and triggering early autophagy in hepatocytes. These mechanistic insights deepen our understanding of HBV persistence and suggest new experimental approaches for studying viral immune evasion.

• Valemetostat (DS-3201): Precision Workflows for Lymphoma Res

  2026-05-04

  Valemetostat (DS-3201) stands out as a first-in-class, dual EZH1/2 inhibitor designed for high-precision interrogation of epigenetic mechanisms in lymphoma. This guide delivers actionable workflows, troubleshooting insights, and protocol optimizations to accelerate translational research—anchored in cutting-edge clinical and preclinical findings.

• Bobcat339: TET Inhibition to Decipher Epigenetic Regulation

  2026-05-03

  This thought-leadership article explores the mechanistic and translational potential of Bobcat339, a cytosine structure-based TET enzyme inhibitor, within the context of DNA methylation, super-enhancer dynamics, and osteogenic differentiation. Drawing from recent multi-omics studies in senile osteoporosis, it provides actionable guidance for researchers navigating epigenetic targets in bone biology, highlighting Bobcat339's role in advancing the study of gene transcription modulation and DNA methylation regulation. The article bridges foundational epigenetics with emerging therapeutic strategies, offering protocol insights, workflow maturity, and a forward-looking perspective.

• Moxifloxacin Workflows: Applied Use-Cases and Troubleshootin

  2026-05-02

  Moxifloxacin stands out as a fluoroquinolone antibiotic uniquely suited for probing antibiotic toxicity, cellular proliferation, and metabolic responses in both in vitro and in vivo research. This guide delivers actionable protocols, optimization strategies, and evidence-backed troubleshooting tips, leveraging APExBIO’s reliable supply of Moxifloxacin to ensure reproducible results.

• NEIL1 Regulates COL17A1 to Promote Colorectal Cancer Initiat

  2026-05-02

  This study uncovers a mechanistic link between oxidative DNA repair and colorectal cancer (CRC) initiation by demonstrating that NEIL1 upregulation enhances tumorigenesis via transcriptional activation of COL17A1. The findings highlight NEIL1 as a potential therapeutic target, especially in combination with NF-κB inhibition, for modulating the immunosuppressive microenvironment in CRC.

• Modified Ethanol Injection Enables Efficient mRNA Lipoplex D

  2026-05-01

  Tang et al. demonstrate that the modified ethanol injection (MEI) method produces mRNA lipoplexes with high protein expression efficiency both in vitro and in vivo. This approach offers a simplified, equipment-light alternative for mRNA delivery, with potential implications for vaccine and gene therapy development.

16095 records 1/1073 page Next 12345 下5页 Last page